Risk Factors in Patients With Rapid Recurrent Hepatitis C Virus–Related Cirrhosis Within 1 Year After Liver Transplantation

Zimmermann, Tim; Otto, Charles W.; Hoppe‐Lotichius, Maria; Biesterfeld, Stefan; Lautem, Anja; Knaak, M.; Zimmermann, Anca; Barreiros, A. P.; Heise, Michael; Schattenberg, Jörn M.; Sprinzl, Martin; Galle, Peter R.; Otto, Gerd; Schuchmann, Marcus

doi:10.1016/j.transproceed.2009.06.120

Cited by 19 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In liver transplant patients, risk factors for progression were increased liver function tests, high viral load and steroid pulse therapy given for rejection. 18 All patients in our study were of course immunosuppressed at some stage but we were unable to show an increased risk for severe liver complications in allogeneic patients with chronic GVHD, suggesting that receiving prolonged immunosuppressive therapy had no influence on the risk for severe liver complications.…”

Section: Discussionmentioning

confidence: 60%

Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy

Ljungman

Locasciulli²,

Soria

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

This prospective study was initiated in 1993 with the aim to study late effects and responses to antiviral therapy in a cohort of hepatitis C virus (HCV)-infected patients. A total of 195 patients were included from 12 centers. In all, 134 patients had undergone allogeneic and 61 autologous hematopoietic SCT (HSCT). The median follow-up from HSCT is currently 16.8 years and the maximum 27.2 years. Overall 33 of 195 patients have died of which 6 died from liver complications. The survival probability was 81.6% and the cumulative incidence for death in liver complications was 6.1% at 20 years after HSCT. The cumulative incidence of severe liver complications (death from liver failure, cirrhosis and liver transplantation) was 11.7% at 20 years after HSCT. In all, 85 patients have been treated with IFN; 42 in combination with ribavirin. The sustained response rate was 40%. The rates of severe side effects were comparable to other patient populations and no patient developed significant exacerbations of GVHD. Patients receiving antiviral therapy had a trend toward a decreased risk of severe liver complications (odds ratio ¼ 0.33; P ¼ 0.058). HCV infection is associated with morbidity and mortality in long-term survivors after HSCT. Antiviral therapy can be given safely and might reduce the risk for severe complications.

show abstract

Section: Discussionmentioning

confidence: 60%

Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy

Ljungman

Locasciulli²,

Soria

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Zimmermann and associates suggested that advanced fibrosis scores at 1 year posttransplant and nonres-ponse to interferon were associated with poor patient and graft survival. 14 However, there are not many studies showing the effects of rapid fibrosis and histologic HCV recurrence on HCC recurrence post-transplant.…”

Section: Resultsmentioning

confidence: 99%

Untitled

2015

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…The variety of relevant confounders exhibiting variable impact, their interaction in genetically unique living individuals resulting from a successful LT have been in the center of attention for many decades. Some risk factors for the development of graft fibrosis have been identified during the scientific attempt to unravel the mystery and to understand the substance of HCV-recurrence in detail [21,29]. However, the majority of observations were based on low sample size.…”

Section: Risk Factorsmentioning

confidence: 99%

“…Progression of graft hepatitis-C seems to be accelerated in patients with HCV-genotype-Ib, high pre-transplant HCV-RNA-load and early post-transplant peak of viremia [29,[35][36][37]. Interestingly, HCVcore protein has been demonstrated to promote inflammation by the release of oxidative stress and to reinforce apoptosis and steatosis.…”

Section: Viral Factorsmentioning

confidence: 99%